Pipeline Insight: Antithrombotics - Anticoagulants and Antiplatelets Have Blockbuster Potential

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-10-04

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor estimates the total revenue generated from new antithrombotics in the seven major markets will reach approximately $10bn by 2015, with novel oral anticoagulants contributing over 70% to this volume. However, barriers to entry exist and developmental antithrombotics must pursue an aggressive development strategy to compete successfully with well-established gold-standard therapies.


Scope

  • Assessment of the patient potential for developmental antithrombotics in the major thrombosis indications over the period 2005-15
  • Overview of the antithrombotic R&D pipeline with detailed information on the classes in development
  • Commercial analysis of key compounds in development in terms of their ability to satisfy unmet needs, supported by the views of key opinion leaders
  • Sales forecasts for key late-stage developmental antithrombotics in the seven major markets to 2015


    • Report Highlights
    After the demise of AstraZeneca's anticoagulant Exanta, Boehringer Ingelheim's BIBR-1048 and Bayer's BAY-597939 are next in line with a chance to switch warfarin-treated patients and grow the market by recruiting the previously untreated population.

    Prasugrel and cangrelor are the most promising developmental antiplatelets with the potential to successfully challenge established drugs such as clopidogrel and GPIIb/IIIa blockers.

    Developmental thrombolytics hold little commercial promise because of established competitors, niche-focused launch strategies, and the overall decline of the thrombolytics market, driven by the increase in cardiovascular surgery.


    Reasons to Purchase

  • Understand the key factors that will contribute to the success of the next generation of antithrombotics
  • Assess and beat the barriers to entry created by the lifecycle strategies of existing market players
  • Find out what market opportunities remain where developmental anticoagulants, antiplatelets and thrombolytics are unable to fulfill unmet needs

    • Table of Contents

    Other users found this report page using the following search terms: antithrombotics anticoagulants thrombosis ncx 4016 2008 prasugrel tenecteplase antiplatelet agents bms562247 apixaban kfa1982

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.